CVS Surges on Regulatory Relief, Medicare Advantage Push: Time to Buy?

CVS Health (CVS) stock has surged 53.7% in 2025, outperforming the S&P 500 and its direct competitors, driven by strong operational performance and a more favorable regulatory environment, specifically the removal of proposed Medicare Advantage and PBM limitations in the Senate tax bill. This regulatory relief benefits CVS' Caremark and Aetna divisions, removing potential constraints on pricing and revenue stability, while CVS' focus on digital care, cost savings, and expanded access further reinforces its growth trajectory. Despite trading at a premium to peers like Walgreens and Herbalife, CVS' discount to the S&P 500 and strategic focus on digital health and value-based care present an attractive entry point for investors.

Analysis

CVS Health has demonstrated significant market outperformance in 2025, with its stock surging 53.7% year-to-date, substantially exceeding the S&P 500's 1.8% rise and the Medical sector's 1.6% decline. This robust performance is attributed to strong operational execution across all business segments, reflected in raised full-year 2025 EPS guidance, and a significantly improved regulatory landscape. Specifically, the removal of proposed limitations on Pharmacy Benefit Managers (PBMs) and cuts to Medicare Advantage programs from the Senate tax bill alleviates near-term policy risks for CVS’s core Caremark and Aetna divisions, respectively. This legislative relief is expected to support Caremark's pricing power and rebate negotiations, and ensure revenue stability for Aetna's expanding Medicare Advantage footprint. Operationally, CVS is enhancing efficiency and access through initiatives such as processing 95% of Aetna's prior authorizations within 24 hours, expanding its bundled cancer care model, and generating over $1 billion in client savings through its low-cost Humira biosimilar, Cordavis. Despite trading at a forward 12-month P/E of 10.37X, a premium to competitors like Walgreens (7.63X) and Herbalife (3.77X), this valuation is a discount to the S&P 500 (21.86X) and is supported by CVS's scale, digital health investments, and focus on value-based care.

Key Decisions for Investors

• Given the strong year-to-date stock performance, positive regulatory shifts benefiting key PBM and Medicare Advantage segments, and upwardly revised EPS guidance, investors may find CVS an attractive investment, aligning with its Zacks Rank #2 (Buy) status.
• The current forward P/E of 10.37X, while at a premium to direct peers, presents a discount relative to the broader S&P 500, potentially offering a favorable entry point for exposure to a diversified healthcare leader with strong growth drivers.
• Investors should monitor the continued execution of CVS's strategic initiatives, particularly in digital innovation, cost-saving measures, and the expansion of value-based care models, as these are critical for sustaining its growth trajectory and market outperformance.